Cisapride treatment for gastro-oesophageal reflux in children.
BACKGROUND
Gastro-oesophageal reflux (GOR) is common and usually self-limiting in infants. Cisapride, a pro-kinetic agent, was commonly prescribed until reports of possible serious adverse events were associated with its use.


OBJECTIVE
To determine the effectiveness of cisapride versus placebo or non-surgical treatments for symptoms of GOR.


METHODS
We searched the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Specialised Register and Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE, reference lists of relevant review articles and searched in the Science Citation Index for all the trials identified. All searches were updated in February 2009.


METHODS
Randomised controlled trials comparing oral cisapride therapy with placebo or other non-surgical treatments for children diagnosed with GOR were included. We excluded trials with a majority of participants less than 28 days of age.


METHODS
Primary outcomes were a change in symptoms at the end of treatment, presence of adverse events, occurrence of clinical complications and weight gain. Secondary outcomes included physiological measures of GOR or histological evidence of oesophagitis. We dichotomised symptoms into 'same or worse' versus 'improved' and calculated summary odds ratios (OR). Continuous measures of GOR (for example reflux index) were summarised as a weighted mean difference. All outcomes were analysed using a random-effects method.


RESULTS
Ten trials in total met the inclusion criteria. Nine trials compared cisapride with placebo or no treatment, of which eight (262 participants) reported data on symptoms of gastro-oesophageal reflux. There was no statistically significant difference between the two interventions (OR 0.34; 95% CI 0.10 to 1.19) for 'same or worse' versus 'improved symptoms' at the end of treatment. There was significant heterogeneity between the studies, suggesting publication bias. Four studies reported adverse events (mainly diarrhoea); this difference was not statistically significant (OR 1.80; 95% CI 0.87 to 3.70). Another trial found no difference in the electrocardiographic QTc interval after three to eight weeks of treatment. Cisapride significantly reduced the reflux index (weighted mean difference -6.49; 95% CI -10.13 to -2.85; P = 0.0005). Other measures of oesophageal pH monitoring did not reach significance. One included study compared cisapride with Gaviscon (with no statistically significant difference). One small study found no evidence of benefit on frequency of regurgitation or weight gain after treatment with cisapride versus no treatment, carob bean or corn syrup thickeners.


CONCLUSIONS
We found no clear evidence that cisapride reduces symptoms of GOR. Due to reports of fatal cardiac arrhythmias or sudden death, from July 2000 in the USA and Europe cisapride was restricted to a limited access programme supervised by a paediatric gastrologist.
Maclennan
Suzanna
S
Department of Neurology, Women's and Childrens Hospital, 72 King William Rd, North Adelaide, SA, Australia, 5006.
Augood
Cristina
C
Cash-Gibson
Lucinda
L
Logan
Stuart
S
Gilbert
Ruth E
RE
D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D020117:Cisapride / Q000009:adverse effects / Q000627:therapeutic use*; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D016032:Randomized Controlled Trials as Topic
D000897:Anti-Ulcer Agents; D005765:Gastrointestinal Agents; D020117:Cisapride
Arch Dis Child Fetal Neonatal Ed. 1999 May;80(3):F174-7
10212076
Eur J Pediatr. 2001 Sep;160(9):572-5
11585082
Arch Pediatr Adolesc Med. 1997 Jun;151(6):569-72
9193240
Clin Ther. 1989 Sep-Oct;11(5):669-77
2805024
Am J Gastroenterol. 2006 Mar;101(3):628-40
16542296
Pediatrics. 1999 Feb;103(2):469-72
9925843
Arch Dis Child Fetal Neonatal Ed. 1998 Sep;79(2):F110-3
9828736
JAMA. 1995 Feb 1;273(5):408-12
7823387
Arch Dis Child. 1992 May;67(5):618-21
1599300
J Paediatr Child Health. 2001 Dec;37(6):559-63
11903835
J Paediatr Child Health. 2000 Dec;36(6):524-9
11115025
Arch Dis Child. 1990 Nov;65(11):1249-54
2248538
J Pediatr Gastroenterol Nutr. 2001 Apr;32(4):458-63
11396814
J Pediatr Gastroenterol Nutr. 1997 Nov;25(5):499-506
9360203
Indian Pediatr. 2000 Aug;37(8):837-44
10951632
J Pediatr Gastroenterol Nutr. 1999 May;28(5):518-28
10328131
Am J Gastroenterol. 1996 Apr;91(4):680-5
8677928
Dev Med Child Neurol. 1996 Nov;38(11):1030-6
8913184
J Pediatr Gastroenterol Nutr. 1991 Jan;12(1):44-7
2061776
Pediatr Pulmonol. 1987 Jan-Feb;3(1):8-12
3588052
J Pediatr Gastroenterol Nutr. 2000 Sep;31(3):232-3
10997363
Gut. 1990 Apr;31(4):370-3
2338260
BMJ. 1997 Sep 13;315(7109):629-34
9310563
Eur J Pediatr. 1993 Sep;152(9):704-11
8223796
Gut. 1990 Jan;31(1):21-5
2180792
J Pediatr. 1999 Mar;134(3):287-92
10064663
Clin Pediatr (Phila). 1991 Jul;30(7):435-40
1879100
Gut. 1993 Nov;34(11):1478-81
8244127
Arch Dis Child. 1987 May;62(5):454-7
3300570